CoreCap Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

CoreCap Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$809	Hold	28	–	–	﹤0.01%	2710
2026 Q2	$601	Hold	28	–	–	﹤0.01%	2816
2026 Q1	$389	Sell	28 -332	-92%	-$5.29K	﹤0.01%	2689
2025 Q4	$5.85K	Sell	360 -53	-13%	-$865	﹤0.01%	2150
2025 Q3	$6.18K	Buy	413 +385	+1,375%	+$4.69K	﹤0.01%	2116
2025 Q2	$326	Hold	28	–	–	﹤0.01%	2568
2025 Q1	$208	Hold	28	–	–	﹤0.01%	2959
2024 Q4	$168	Hold	28	–	–	﹤0.01%	2740
2024 Q3	$143	Hold	28	–	–	﹤0.01%	2534
2024 Q2	$101	Hold	28	–	–	﹤0.01%	1535
2024 Q1	$90	Buy	+28	New	+$108	﹤0.01%	2450

Other funds holding ADPT

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

Edge Wealth Management New York $666M AUM 17.64% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

GWM

Gibbs Wealth Management Alpharetta, Georgia $955M AUM 18.67% 1-Year Est. Return

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Warsaw $291M AUM 52.67% 1-Year Est. Return

WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return

CoreCap Advisors's ADPT Position: Q3 2026 in Review

CoreCap Advisors held its Adaptive Biotechnologies (ADPT) position steady in Q3 2026 at 28 shares worth $809. The position accounts for ﹤0.01% of the portfolio, ranked #2710.

CoreCap Advisors first reported a position in ADPT in Q1 2024 and has held it in 11 quarters since. The position peaked at $6.18K in Q3 2025. 41 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

CoreCap Advisors held 28 shares of Adaptive Biotechnologies worth $809 as of Q3 2026.
CoreCap Advisors left its Adaptive Biotechnologies share count unchanged in Q3 2026.
Adaptive Biotechnologies made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2710 holding.
CoreCap Advisors first reported a position in Adaptive Biotechnologies in Q1 2024 and has held it in 11 quarters since.
CoreCap Advisors's Adaptive Biotechnologies position peaked at $6.18K in Q3 2025.
41 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.